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Functional inorganic nanomaterials with good biocompatible, excellent physical
and chemical properties, easy modification, and tunable size and morphology
have been widely used in biomedical. Since magnetic resonance imaging (MRI)
contrast agent and inorganic drug delivery systems can improve the accuracy and
efficiency in cancer diagnosis and therapy, development of new and effient
inorganic nanomaterials in drug delivery and MRI contrast agent are highly
desirable and important. In this dissertation, we have developed kinds of
functional inorganic nanomaterials to achieve accurate diognosis and effective
therapy to tumor. The main investigations are summarized as follows:
Chapter 1. Recent research progress of functional inorganic nanomaterials in MRI
contrast agent and drug delivery systems have been briefly reviewed. Besides,
we also demonstrated the research significance and content in this thesis.
Chapter 2. We report a new strategy to achieve extremely high transverse
relaxivity by controlling the morphology of Fe3O4 nanoparticles. We successfully
fabricate size-controllable octapod Fe3O4 nanoparticles by introducing chloride
anions. The octapod Fe3O4 nanoparticles (edge length of 30 nm) exhibit an
ultrahigh r2 value, indicating that these octapod Fe3O4 nanoparticles are much
more effective T2 contrast agents for in vivo MRI and small tumor detection
comparing to conventional iron oxide nanoparticles, which holds great promise for
highly sensitive, early stage and accurate detection of cancer in the clinic.
Chapter 3. We have demonstrated hexagonal Fe3O4 nanosheets can be
prepared by introducing of chloride anions. The prepared Fe3O4 nanosheets are
enclosed by (111) facets. We demonstrate that the main contribution of the T1
contrast of magnetic nanoparticles is the chemical exchange between photon and
iron ion on the surface of nanoparticles. Since the (111) facet is an iron-rich facet,













traditional spherical Fe3O4 nanoparticles.
Chapter 4. We demonstrate that cation exchange can engineer the composition of
iron oxide nanocrystals to significantly improve the magnetic resonance contrast
ability in molecular imaging. We successfully construct manganese or zinc doped
iron oxide nanoparticles with diverse shapes (sphere, cube, and octapod) by
facile cation exchange reactions. The engineered shaped-anisotropic iron oxide
nanoparticles exhibit both high saturated magnetization values and large effective
boundary radii, which ensures the extremely high r2 values. The engineered iron
oxide nanoparticles with ultrahigh relaxivity serve as high-performance T2
contrast agents for in vivo imaging, early tumor detection, and high-sensitive
metastatic tumor diagnosis, particularly hepatic carcinomas.
Chapter 5. We describe a smart and targeted magnetic nanocarriers to control the
delivery and release of anticancer drug doxorubicin (DOX) in vitro. The
conjugation of targeted magnetite nanoparticles and DOX molecule via acid-labile
imine bonds endows the nanocarriers with three advanced features: magnetically
controllable, specific targeting, and pH-responsive. These advantages endow the
intelligent drug delivery system to improve the chemotherapeutic efficacy and
reduce the side effects, which has great potential to become a favorable strategy
for delivery of drugs to the desired sites in patients.
Chapter 6. We report a facile strategy to achieve high anticancer activity of
arsenic trioxide by loading the nanoparticulate prodrug into hollow silica inorganic
nanoparticles. Because of the appropriate size, pH sensitivity, and surface
targeted modification, this smart nanosized drug delivery system can deliver
arsenic trioxide into cancer cells efficiently and exhibit much higher cytotoxicity to
a variety of cancer cells than free arsenic trioxide. Moreover, this nanomedicine
can further promote the differentiation and inhibit the migration of cancer cells. In
vivo results suggest that this drug delivery system can significantly inhibit the













Chapter 7. We reported an ATO-based multifunctional drug delivery system that
efficiently delivers ATO to treat tumors and allows real-time monitoring of ATO
release by activatable T1 imaging. Acidic stimuli triggered the simultaneous
release of manganese ions and ATO, which dramatically increase the T1 signal
(bright signal) and enabled real-time visualization and monitoring of ATO release
and delivery. Moreover, this smart multifunctional drug delivery system
significantly improve ATO efficacy and strongly inhibit the growth of solid tumors
without adverse side effects.
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